FDA Guidance on Artificial Intelligence in Drug and Biological Product Development
Published March 2026 — Analysis of the FDA's evolving framework for AI in regulatory decision making, including the 7-step credibility assessment, the joint FDA/EMA Guiding Principles, and operational implications for sponsors and clinical research sites.
From Tool to Regulated Evidence Source
Artificial intelligence and machine learning have moved rapidly from experimental tools to core infrastructure across the drug development lifecycle. Sponsors now use AI for patient identification, eligibility screening, dose-response modeling, safety signal detection, and post-market pharmacovigilance. The pace of adoption has outstripped the regulatory community’s historical framework for evaluating evidence — a framework that assumed evidence sources were transparent, deterministic, and human-interpretable.
The FDA’s January 2025 draft guidance, “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products,” was the agency’s first comprehensive attempt to apply a coherent regulatory standard to AI-derived evidence. The guidance does not regulate AI per se; instead, it establishes how sponsors must assess and demonstrate the credibility of AI model outputs when those outputs are used to support regulatory decisions. The 90-day public comment period closed on April 7, 2025, and the agency received extensive input from industry, academia, and patient organizations.
In January 2026, the FDA and EMA jointly published the “Guiding Principles of Good Machine Learning Practice for Drug Development,” a set of ten high-level principles designed to align international expectations and complement the credibility framework. The final FDA guidance, incorporating comment-period revisions and alignment with the joint principles, is expected in Q2 2026. The agency has also announced an AI-Enabled Optimization of Early-Phase Clinical Trials pilot program, with a Request for Information published in the Federal Register on April 29, 2026.
The 7-Step Credibility Assessment Framework
The centerpiece of the draft guidance is a risk-based credibility assessment framework that sponsors must apply when using AI to generate or analyze evidence for regulatory submission.
The framework follows a defined sequence: define the question of interest, define the context of use, characterize the AI model, assess model risk, develop a credibility assessment plan, execute the plan and document results, and determine adequacy of credibility evidence for the intended use. Each step has documentation expectations that must be reflected in the regulatory submission.
The required depth of credibility evidence scales with how influential the AI output is on the regulatory decision. AI models used for preliminary triage or hypothesis generation require less rigorous credibility documentation than models whose output directly drives safety or efficacy claims. The framework explicitly avoids a one-size-fits-all standard.
The guidance applies to nonclinical, clinical, postmarketing, and manufacturing phases. AI used for patient recruitment in Phase II, safety signal detection in Phase III, and post-market pharmacovigilance must each be evaluated under the same conceptual framework, with the credibility assessment tailored to the specific use case.
Sponsors must submit a Credibility Assessment Plan that comprehensively documents model design, training data provenance and curation, performance evaluation methodology, intended use boundaries, and ongoing monitoring approach. The CAP becomes part of the regulatory file and is reviewed alongside the model output evidence.
Regulatory Rollout Timeline
The FDA has staged the evolution of AI regulatory expectations across multiple milestones, with each step expanding the practical implications for sponsors and sites using AI in clinical research.
Draft Guidance Released (January 2025)
The FDA published the draft guidance “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products” in January 2025, introducing the 7-step credibility framework. The release marked the first comprehensive FDA position on AI evidence in drug development and triggered a 90-day public comment period closing April 7, 2025.
Joint FDA/EMA Guiding Principles (January 2026)
The FDA and EMA jointly published ten Guiding Principles of Good Machine Learning Practice for Drug Development. The principles emphasize that AI should support but not replace human regulatory decision-making, that risk-based assessment must be the foundation of credibility evaluation, and that documentation must be sufficient for regulatory reviewers to independently evaluate model behavior. The joint principles align FDA and EMA expectations and reduce divergent compliance burden for sponsors operating across both regions.
AI-Enabled Early-Phase Pilot Program (April 2026)
The FDA published a Request for Information in the Federal Register on April 29, 2026, launching the AI-Enabled Optimization of Early-Phase Clinical Trials pilot program. The pilot will provide selected sponsors with direct FDA technical engagement on AI-driven trial designs in Phase I and early Phase II, including adaptive randomization algorithms, dose-finding models, and AI-augmented patient selection. Lessons from the pilot are expected to inform a subsequent FDA guidance on AI-driven trial design.
Final Guidance Expected (Q2 2026)
The FDA has signaled that final guidance is expected in Q2 2026, incorporating comment-period revisions and alignment with the joint FDA/EMA principles. The final document is expected to clarify several issues raised during the comment period, including the level of credibility evidence required for AI used in patient recruitment, the treatment of foundation models and large language models, and the boundary between AI as a regulatory evidence source and AI as an operational efficiency tool.
Real-Time Trial Monitoring Pilot (2026–2027)
In parallel with the guidance pathway, the FDA announced a real-time clinical trial data monitoring pilot in April 2026, which will use cloud infrastructure and AI to monitor trial data in near-real-time. FDA officials have publicly stated that the program could ultimately reduce clinical trial timelines by 20-40%. Sites participating in this pilot will see new expectations around source data access, monitoring infrastructure, and data flow latency from EDC to regulator-facing systems.
Site-Level Implications
While the credibility framework is primarily a sponsor obligation, sites that participate in AI-augmented trials will see new documentation, infrastructure, and operational expectations.
When sponsors use AI-driven patient identification or eligibility screening, sites become a data-flow node in the credibility chain. Sites should expect documentation requests covering the AI model’s use of site-provided EHR data, the protocols for human verification of AI-flagged candidates, and the audit trail linking AI recommendations to actual enrollment decisions. Sites should formalize their internal procedures for AI-assisted screening to support sponsor credibility documentation.
AI model credibility depends on the quality of the data the model consumes. Sites that contribute data to AI models for safety monitoring, endpoint adjudication, or efficacy analysis will see heightened expectations around data completeness, timeliness, and consistency. Late or incomplete source data has always been a quality concern; in AI-driven workflows it becomes a model credibility issue that may have regulatory consequences.
The FDA’s real-time monitoring pilot will require sites to support near-real-time data flow from EDC to sponsor and regulator systems. This represents a substantial shift from current monthly or quarterly data lock cadences and will require sites to maintain higher levels of source data verification, query resolution, and data entry timeliness on an ongoing basis rather than concentrated around interim analysis milestones.
The joint FDA/EMA principles emphasize that AI must support rather than replace human regulatory and clinical decision-making. For sites, this means that investigator oversight responsibilities — particularly around eligibility determinations, safety assessments, and adverse event adjudication — remain fundamentally human. Investigators cannot delegate clinical judgment to AI outputs, even when those outputs are presented as decision support. Investigator oversight documentation should explicitly capture the human review applied to AI-flagged determinations.
The guidance highlights algorithmic bias as a credibility risk, particularly for AI models trained on historical EHR data that may reflect existing disparities in clinical care access. Sites participating in AI-augmented recruitment should track and report whether AI-flagged candidate populations differ demographically from the broader site population. Persistent demographic skew in AI-flagged candidates may indicate model bias that must be addressed.
FDA inspections of AI-augmented studies are expected to focus on the audit trail between AI outputs and clinical decisions. Sites should ensure that AI-assisted activities are documented with the same rigor as traditional source documentation: who reviewed the AI output, what action was taken, what training the reviewer had, and how the outcome was documented in source records. The credibility framework makes this audit trail a regulator-facing expectation.
What This Means for Sponsors
For sponsors, the AI guidance reframes how AI investments must be planned and executed. AI tools that previously fell into the operational efficiency category — patient identification, protocol authoring assistance, data cleaning — now face credibility documentation expectations when their outputs influence regulatory decisions. The cost of an AI tool no longer ends at procurement; it extends to the regulatory documentation and ongoing monitoring infrastructure required to qualify the tool’s outputs for regulatory use.
Strategic sponsors are responding by establishing internal AI governance frameworks that classify each AI use case by regulatory risk, develop credibility assessment templates for common use cases, and engage early with FDA review divisions when AI is central to a development program. Pre-IND meetings now routinely include AI use disclosures, and sponsors who address credibility proactively report shorter review cycles than those who wait for FDA to request credibility documentation reactively.
The longer-term opportunity is significant. As FDA piloting validates AI-driven trial designs and real-time monitoring, sponsors who have mature AI governance will be positioned to take advantage of accelerated review pathways and shorter trial durations. Sponsors who continue to treat AI as a back-office tool — separate from regulatory strategy — risk falling behind both on capability and on regulatory throughput.
Clinitiative Network Readiness
The Clinitiative network has built site-level capabilities to support AI-augmented trial designs and to meet the documentation expectations emerging from the FDA framework.
38 sites in the Clinitiative network have integrated AI-augmented patient screening platforms with their EHR systems. Each site maintains documented review procedures and human-verification audit trails compatible with the FDA credibility framework's expectations for AI-assisted recruitment.
All Clinitiative network sites operate EDC configurations that support continuous data flow, enabling participation in real-time monitoring studies. Source data verification and query resolution are managed on a continuous workflow rather than a batched cadence, supporting the FDA's emerging real-time monitoring expectations.
All investigators in the Clinitiative network have completed structured training on AI use in clinical research, covering the joint FDA/EMA principles, the credibility framework, and the documentation expectations for AI-assisted clinical judgment. Training is refreshed annually as the regulatory framework evolves.
Sites participating in AI-augmented studies report demographic data on AI-flagged candidates as part of the standard enrollment reporting workflow. This allows sponsors to detect demographic skew in AI recommendations early in enrollment and to adjust model parameters or recruitment strategies before bias compounds.
Navigating AI in Your Development Program?
Talk with our regulatory affairs team about how the Clinitiative network supports AI-augmented trial designs and credibility documentation.